v3.26.1
Collaborations, contracts and licensing agreements (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Summary of collaborations
Revenues are summarized in the following table:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(in thousands)(in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc.$202 $591 $406 $1,095 
Qilu Pharmaceutical Co., Ltd.— 9,622 — 10,434 
License revenue from Genevant632 — 179,373 — 
Non-cash royalty revenue
Alnylam Pharmaceuticals, Inc.180 526 361 974 
Total revenue$1,014 $10,739 $180,140 $12,503